Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Journal of Diabetes and its Complications, Volume 29, No. 8, Year 2015
Notification
URL copied to clipboard!
Aim Recent in vitro researches have shown that plasma Lp(a) can be reduced using a proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitory monoclonal antibody. In our clinical study we tried to investigate the association between plasma Lp(a) and PCSK9 in Type 2 diabetic patients with elevated plasma Lp(a), and to check whether such an association would be related to LDL-receptor (LDL-R) levels. Methods Plasma PCSK9 and LDL-R concentrations were measured by sandwich ELISA methods using recombinant human PCSK9 protein and LDL-R protein as standards in a cohort with type 2 diabetic patients (n = 50) compared to an age- and sex-matched control group (n = 50). Both clinical and biochemical parameters were determined in all patients. Results Plasma PCSK9 level was significantly elevated in T2DM patients compared to controls (44.61 ± 14.44 and 33.22 ± 11.79 ng/mL, respectively, P < 0.0001). However LDL-R levels did not differ between the two groups. Remarkably, plasma PCSK9 levels were positively correlated with Lp(a) levels in whole population (r = + 0.227, P = 0.03) as well as in T2DM group (r = + 0.398, P = 0.0061) but not in control group. Multiple linear regression analysis showed that plasma Lp(a) levels were independently associated to those of PCSK9. Conclusion Lp(a) has been proposed as a contributing factor to the accelerated development of macrovascular complications in T2DM. Its synergic effect with PCSK9 may explain the enhanced atherogenicity in T2DM patients.